Artificial intelligence in medical device software and high-risk medical devices – a review of definitions, expert recommendations and regulatory initiatives
Alan G Fraser,Elisabetta Biasin,Bart Bijnens,Nico Bruining,Enrico G Caiani,Koen Cobbaert,Rhodri H Davies,Stephen H Gilbert,Leo Hovestadt,Erik Kamenjasevic,Zuzanna Kwade,Gearóid McGauran,Gearóid O’Connor,Baptiste Vasey,Frank E Rademakers
DOI: https://doi.org/10.1080/17434440.2023.2184685
IF: 3.439
2023-05-10
Expert Review of Medical Devices
Abstract:Artificial intelligence (AI) encompasses a wide range of algorithms with risks when used to support decisions about diagnosis or treatment, so professional and regulatory bodies are recommending how they should be managed. AI systems may qualify as standalone medical device software (MDSW) or be embedded within a medical device. Within the European Union (EU) AI software must undergo a conformity assessment procedure to be approved as a medical device. The draft EU Regulation on AI proposes rules that will apply across industry sectors, while for devices the Medical Device Regulation also applies. In the CORE-MD project (Coordinating Research and Evidence for Medical Devices), we have surveyed definitions and summarize initiatives made by professional consensus groups, regulators, and standardization bodies. The level of clinical evidence required should be determined according to each application and to legal and methodological factors that contribute to risk, including accountability, transparency, and interpretability. EU guidance for MDSW based on international recommendations does not yet describe the clinical evidence needed for medical AI software. Regulators, notified bodies, manufacturers, clinicians and patients would all benefit from common standards for the clinical evaluation of high-risk AI applications and transparency of their evidence and performance.
engineering, biomedical